Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Therapeutic effects of novel sphingosine-1-phosphate receptor agonist W-061 in murine DSS colitis.
Combined central and peripheral demyelination: Clinical features, diagnostic findings, and treatment.
Balance impairment in people with multiple sclerosis: Preliminary evidence for the Balance Evaluation Systems Test.
Anti-myelin oligodendrocyte glycoprotein antibodies in pediatric patients with optic neuritis.
Clinical and MRI characterization of MS patients with a pure and severe cognitive onset.
Considering the influence of stimulation parameters on the effect of conventional and high-definition transcranial direct current stimulation.
Prolonged Toxic Encephalopathy following Accidental 4-Aminopyridine Overdose.
Axonal and oligodendrocyte-localized IgM and IgG deposits in MS lesions.
English Court of Appeal finds in favor of Teva on Copaxone(R) patent litigation and upholds validity of Copaxone patent until May 2015
B-07The Cognitive Health Questionnaire: Initial Psychometric Data in a Multisite Multiple Sclerosis Sample.
Targeted Stage-Specific Inflammatory microRNA Profiling in Urine During Disease Progression in Experimental Autoimmune Encephalomyelitis: Markers of Disease Progression and Drug Response.
Positive year one results from Biogen Idec's Phase 3 advance trial of PLEGRIDY™ (peginterferon beta-1a) presented at AAN meeting
Long-term safety and efficacy of teriflunomide: Nine-year follow-up of the randomized TEMSO study.
A gradient in cortical pathology in multiple sclerosis by in vivo quantitative 7 T imaging.
Increase in NF-κB-sensitive miRNA-146a and miRNA-155 in multiple sclerosis (MS) and pro-inflammatory neurodegeneration.
The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain.
Rare variants in the CYP27B1 gene are associated with multiple sclerosis.
A 2-year observational study of patients with relapsing-remitting multiple sclerosis converting to glatiramer acetate from other disease-modifying therapies: the COPTIMIZE trial.
Interferon beta 1b following natalizumab discontinuation: one year, randomized, prospective, pilot trial.
Asymptomatic lung disease caused by Mycobacterium kansasii as an opportunistic infection in a patient treated with natalizumab for relapsing-remitting multiple sclerosis.
Lipocalin 2 is present in the EAE brain and is modulated by natalizumab.
Valproic acid ameliorates inflammation in experimental autoimmune encephalomyelitis rats.
RGC-32 as a potential biomarker of relapse and response to treatment with glatiramer acetate in multiple sclerosis.
Ozanimod (RPC1063) is a potent sphingosine-1-phosphate receptor-1 (S1P1R ) and receptor-5 (S1P5R ) agonist with autoimmune disease-modifying activity.
Fatigue, depression and sleep disturbances in Iranian patients with multiple sclerosis.

Pages